Guilford restructuring
Executive Summary
Guilford plans to reduce its workforce by approximately 25% to 220 employees following suspension of several R&D programs and a decision to focus on more advanced clinical projects. The company will concentrate on the anesthetic agent Aquavan (propofol pro-drug) and the Parkinson's disease agent GPI-1485, both in Phase II studies. Guilford expects to take a restructuring charge of up to $1.5 mil. in the third quarter. The program is expected to result in estimated annualized savings of approximately $10 mil.-$12 mil., beginning in 2003...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.